The chief executive of Memorial Sloan Kettering Cancer Center, Craig Thompson, resigned from Merck’s board of directors, following media investigations about the center’s ties to the pharma industry.
Thompson also resigned from the board of lab services firm, Charles River Laboratories International.
The move follows the resignation of Sloan Kettering’s chief medical officer, Jose Baselga, in September, after The New York Times and ProPublica reported that he had failed to disclose millions of dollars in payments from pharma companies in dozens of articles he had written for medical journals.
“I have taken feedback from our staff and faculty seriously and intend to lead by example,” said Thompson in a statement.
Read the Reuters coverage
[javascriptSnippet]